Gene Solutions received FDA Breakthrough Device Designation for SPOT-MAS 10, a blood-based multiomics early detection test that screens asymptomatic adults for ten cancer types. The designation covers an adjunctive lab-developed test using circulating cell-free DNA (cfDNA) assessed by methylation and fragmentomic signatures. The assay’s label-enriched scope includes breast, lung, liver, colorectal, and gastric cancers, plus ovarian, pancreatic, esophageal, endometrial, and head-and-neck malignancies. Gene Solutions said the test uses machine learning to interpret signals from cfDNA. The company previously partnered with Pangea Laboratories to support U.S.-based analytical and clinical validation, which is designed to facilitate subsequent FDA pathways for broader clinical deployment. For the field, the Breakthrough designation signals regulatory interest in multiomics liquid biopsy approaches that aim to improve early detection sensitivity and clinical utility across multiple tumor types.